-
Product Insights
Pyelonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Pyelonephritis - Drugs In Development, 2023’, provides an overview of the Pyelonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Urinary Tract Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Tract Infections - Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Company Profile
Novelis Inc – Company Profile
Novelis Inc (Novelis), a subsidiary of Hindalco Industries Ltd, is a producer of flat-rolled aluminum products and a recycler of aluminum. The company’s product portfolio includes sheet ingot, foils, recycled aluminum, can stock, electronic products, and HVAC material. It also offers various sheets such as automotive sheets, industrial sheets, construction sheets, and painted sheets. The company offers these products to transportation, packaging, architectural, industrial and consumer durables and other markets. It sells alloy products to automakers under the brand Novelis...
Add to Basket -
Company Profile
Societal CDMO Inc – Company Profile
Societal CDMO Inc (Societal CDMO), formerly Recro Pharma Inc, provides contract development and manufacturing organization (CDMO) services. The company harnesses formulation capabilities and proprietary delivery technologies for the development, manufacture, and commercialization of pharmaceutical products of its partners. It manufactures products such as Ritalin LA, Verelan SR, Focalin XR, Verelan PM, Verapamil PM, Verapamil SR, Donnatal liquids and tablets with commercial partners. The company’s commercial partners include as Teva, Novartis, Lannett, Advanz and Infectopharma. It also provides services such as...
Add to Basket -
Sector Analysis
Fragile X Syndrome – Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2030
The Fragile X syndrome (FXS) market size in the 2MM was valued at $21.9 million in 2020. The market is projected to grow at a CAGR of over 7% during the forecast period. Since there are currently no approved therapies available, prescribed treatments are exclusively off-label drugs that target individual symptoms of the disease. Despite behavioral and educational interventions, patients with FXS continue to present with significant impairments in their functioning throughout life. It is suggested that an FXS-specific treatment...
-
Track & Monitor
Pharmaceuticals Industry Deals and Trends in January 2021 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)
GlobalData's "Pharmaceuticals Industry Deals and Trends in January 2021 - Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2021. The report portrays detailed comparative data on the number of deals and their value...
-
Product Insights
Edema Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Edema Global Clinical Trials Review, H1, 2019" provides an overview of Edema clinical trials scenario. This report provides top line data relating to the clinical trials on Edema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Cholelithiasis Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Cholelithiasis Global Clinical Trials Review, H2, 2018" provides an overview of Cholelithiasis clinical trials scenario. This report provides top line data relating to the clinical trials on Cholelithiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Cholestasis Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Cholestasis Global Clinical Trials Review, H2, 2018" provides an overview of Cholestasis clinical trials scenario. This report provides top line data relating to the clinical trials on Cholestasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Edema Disease – Global Clinical Trials Review, H2 2019
GlobalData's clinical trial report, “Edema Global Clinical Trials Review, H2, 2019" provides an overview of Edema clinical trials scenario. This report provides top line data relating to the clinical trials on Edema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...